Introduction
Gene therapy is a novel approach for the treatment of malignancies resistant to traditional therapeutic modalities.
1-3 To achieve therapeutic gene delivery, adenoviral vectors (Ad) have been employed owing to their ability to achieve superior levels of in vivo gene transfer compared to alternative vector systems. 2 However, despite promising preclinical results obtained in model systems, the major limitation in clinical applications precluding positive outcomes has been inefficient transduction of target tissues by the routinely used human adenovirus serotype 5 vector (Ad5). This problem is mainly due to the insufficient levels of the primary adenoviral receptor, coxsackie-adenovirus receptor (CAR), on target cancer cells. 4, 5 In particular, it has been demonstrated that ovarian and breast cancer cells exhibit relative resistance to adenoviral transduction as a result of CAR deficiency. 6, 7 This observation predicates the need to develop strategies to alter adenovirus tropism for the goal of efficient gene delivery to cancer cells via 'CAR-independent' pathways.
A general approach to achieve tropism modification is based on genetic modification of certain adenoviral capsid proteins involved in viral binding and target cell entry. Such strategies have largely been directed towards modification of the adenoviral fiber capsid protein, which recognizes the primary receptor CAR. Methods to incorporate heterologeous-binding proteins have exploited locales at the fiber carboxy-terminus and the fiber-knob HI-loop. 8, 9 In addition, the approach of fiberknob serotype chimerism takes advantage of the fact that a subset of human adenovirus serotypes recognize non-CAR primary cellular receptors. 10, 11 These various strategies have been successfully employed to achieve a CAR-independent infection capacity for Ad5 vectors. Of note, redirecting the binding of Ad5 to alternate receptors has allowed infectivity enhancement in CARdeficient, Ad5-refractory tumor targets. 4, 12, 13 Not as rigorously explored, and perhaps more radical, is a recently described approach entailing the development of Ad 'xenotypes'. 14 In this scheme, the fiber-knob of a non-human adenovirus is incorporated into the capsid of a human Ad5 vector to confer novel tropism. Non-human adenoviruses, including those from avian, bovine, porcine, primate, feline, ovine, and canine hosts, [15] [16] [17] represent an underused resource in vector design which could offer alternate cellular entry pathways for adenovirus vectors. Although some of these viruses are being developed as gene delivery vectors themselves, 16 the substitution of the Ad5 fiber-knob with these various xenotype fiber-knobs provides an efficient means to analyze their tropism in the context of an Ad5 vector that has been rigourously studied and for which molecular methods have been well established. 2 Previously, we exploited the unique tropism of canine adenovirus serotype 2 (CAV-2) 18 to generate an Ad5/ CAV-2 chimeric vector, which exhibited profound infectivity enhancement of CAR-deficient human tumor cell targets.
14 Another canine adenovirus strain, serotype 1 (CAV-1), has also been partially characterized. Whereas, its cell entry biology has not been described to the extent that has been accomplished for CAV-2, the pathological, structural, biophysical, and serological dissimilarities of CAV1 [19] [20] [21] [22] [23] [24] in comparison to CAV-2 suggest that a distinct underlying tropism may be operational. In light of these considerations, we explored the potential utilization of an adenoviral xenotype possessing the fiber-knob of CAV-1.
Results
Generation of an Ad5 vector containing a chimeric fiber with the CAV-1 knob domain Applying structural knowledge of the human Ad5 fiber protein 25 in the context of the CAV-1 fiber indicates that the CAV-1 fiber consists of an N-terminal tail of about 42 amino acids (aa), a shaft of 321 aa, and a remaining C-terminus of 179 aa forming the knob (Figure 1a) . 26 A conserved threonine-leucine-tryptophan-threonine (TLWT) motif at the N-terminus of the fiber-knob domain is present in most mammalian Ads including CAV-1. A chimeric fiber was constructed by substitution of the Ad5 fiber-knob with the coding region of the CAV-1 knob domain while preserving the TLWT motif common to both Ad5 and CAV-1 fibers. This procedure was performed by using a two-plasmid rescue system essentially as described by Krasnykh et al.
11
We generated an E1-deleted recombinant Ad genome (Ad5Luc1-CK1) incorporating the chimeric Ad5 fiber shaft/CAV-1 knob gene along with a firefly luciferase reporter gene controlled by the CMV immediate early promoter/enhancer in the E1 region. Genomic clones of Ad5Luc1-CK1 were sequenced, and two correct clones 2) and Ad5Luc1 with wild-type Ad5 fiber (lanes 3 and 4) were resuspended in Laemmli buffer before SDS-PAGE and Western analysis with an antitail fiber mAb. The samples in lanes 1 and 3 were heated to 951C before electrophoresis. Fiber monomers (M) and trimers (T) are indicated. The markers represent molecular mass in kilodaltons.
Novel expanded tropism for cancer gene therapy MA Stoff-Khalili et al were chosen. Following transfection into HEK 293 cells, cytopathic effect was observed between 8 and 9 days post-transfection. Large-scale preparations of Ad5Luc1-CK1 and the Ad5Luc1 control vector were produced and purified by double cesium chloride gradient centrifugation. Of note, we applied isogenic vectors in this study based on the Ad5 genome, displaying either the Ad5 knob (Ad5Luc1), CAV1 knob (Ad5Luc1-CK1), or the CAV2 knob (previously named Ad5Luc1-CK but designated here as Ad5Luc1-CK2 for ease of distinction).
14 Using a common scheme would standardize vectorrelated properties including the reporter gene expression cassette and capsid structure while allowing analysis of gene transfer function as a result of modifying the knob.
The fiber-knob genes of Ad5Luc1 and Ad5Luc1-CK1 were confirmed by PCR using designed primer pairs to specifically amplify the respective knob domains from purified viral genome templates (Figure 1b) . Trimerization of the chimeric fiber from viral particles was analyzed by SDS-PAGE followed by Western blot analysis. The monoclonal 4D2 primary antibody which recognizes the Ad5 fiber tail domain common to both wild type Ad5 and chimeric fiber molecules was used.
Bands of approximately 200 kDa molecular weight corresponding to the nondenatured trimeric fiber molecule for both Ad5Luc1-CK1 and control virions were observed. On the other hand, bands from boiled samples of the same viruses resolved at an apparent molecular mass of approximately 70 kDa, indicative of the fiber monomer form (Figure 1c) . Thus, both the correct sequence integrity and trimerization of Ad5Luc1-CK1 were confirmed.
Distinct binding and gene transfer properties of Ad5Luc1-CK1 and Ad5Luc1-CK2
The rationale for developing our novel Ad5Luc1-CK1 vector was founded on the hypothesis that the CAV-1 knob tropism is distinct from the CAV-2 knob tropism based on differences in the pathobiologies of the viruses during infection in their native canine hosts. To validate this concept, we first evaluated the receptor-binding properties of Ad5Luc1-CK1 (Figure 2a and b) and Ad5Luc1-CK2 (Figure 2c and d) on A549 human lung cancer cells in a recombinant knob competitive inhibition assay employing FACS-based detection of surface-bound virions. As a control, Ad5Luc1 cell binding was also analyzed with Ad5 knob protein blocking (Figure 2e) . Interestingly, the data obtained in this competitive inhibition experiment show that the CAV-2 fiber-knob protein cannot effectively block the Ad5Luc1-CK1 cell binding (Figure 2b ) whereas the CAV-1 fiber-knob protein can inhibit Ad5Luc1-CK2 cell binding ( Figure  2d ) to the same extent that each recombinant knob can prevent cell interaction of its respective vector.
To further confirm the distinction between Ad5Luc1-CK1 and Ad5Luc1-CK2-mediated tropism as indicated by the cell-binding assay, we sought to block Ad5Luc1-CK1 and Ad5Luc1-CK2-mediated gene transfer in DK dog kidney and SKOV3.ip1 ovarian cancer cells with the recombinant knob proteins. The data obtained in this competitive inhibition gene transfer experiment show that the CAV-2 knob protein can partially block Ad5-Luc1-CK1 gene transfer in only SKOV3.ip1 cells but not completely (Figure 3a) . However, the CAV-1 knob can competitively block Ad5Luc1-CK1 gene transfer with increasing concentrations (Figure 3b) . Conversely, the CAV-1 knob protein can totally inhibit Ad5Luc1-CK2 gene transfer in all tested cell lines (Figure 3c ) in the same manner that the CAV-2 knob can mediate inhibition of Ad5Luc1-CK2 gene transfer (Figure 3d ). These findings are consistent with the results of the cell-binding assay ( Figure 2 ) and suggest the possibility of a common receptor between the CAV-1 and CAV-2 knobs although the Ad5Luc1-CK1 displayed a binding property distinct from the Ad5Luc1-CK2.
Since CAV-2 has been shown to bind to CAR, 14, 27 we investigated whether CAR may be a common receptor for the CAV-1 and CAV-2 knobs. For this reason, we performed a blocking experiment of Ad5Luc1-mediated gene transfer in U118-hCAR-tailless cells (a CAR-positive U118 cell line variant that heterelogously expresses the extracellular domain of human CAR 28 ) with CAV-1 and CAV-2 fiber-knob proteins. Ad5 fiber-knob protein was used as a control. Ad5Luc1 transduction in U118-hCARtailless cells was strongly blocked by all three CAV-1 (95%), CAV-2 (98%), and Ad5 fiber-knob proteins (98%) (data not shown), confirming that all three knobs can interact with the CAR receptor.
Infectivity enhancement of CAV-1 knob xenotype Ad in CAR-deficient cells
Our central goal was to investigate whether the CAV1 'xeno-knob' paradigm would mediate increased transduction in CAR-deficient target cancer cells. To evaluate the CAR-independent receptor-binding properties of our novel Ad5Luc1-CK1 vector in comparison with Ad5-Luc1, CAR-deficient U118MG glioma cell line and its CAR-positive variant U118-hCAR-tailless, which artificially expresses the extracellular domain of human CAR, were used in a cell-binding assay as described above. In CAR-deficient cells U118MG, only a modest level of cell surface-associated Ad5Luc1 (38%) was detected ( Figure  4a ). In contrast, 81% of the CAR-positive variant line U118-hCAR-tailless cells were positive for Ad5Luc1 binding ( Figure 4b ). Importantly, our novel vector Ad5Luc1-CK1 exhibited a remarkable 95% cell surface binding in U118 MG (glioma) cells ( Figure 4a ) and cell interaction comparable to that of Ad5Luc1 in U118-hCAR-tailless cells (Figure 4b ).
Successful initial attachment on the cell surface via fiber-knob interaction does not necessarily result in increased gene transfer. To validate effective gene delivery conferred by the binding properties of the CAV-1 knob, we evaluated Ad5Luc1-CK1-mediated gene transfer in the U118MG and U118-hCAR-tailless cell lines ( Figure 5 ). Ad5Luc1 (containing the wild-type Ad5 fiber), Ad5Luc1-CK2, and Ad5/3Luc1, (containing the Ad5 fiber shaft and the Ad3 knob) were used as controls. Ad5Luc1 exhibited clear CAR-dependent tropism as demonstrated by a 100-fold increase in transgene expression in U118-hCAR-tailless cells versus the CARdeficient U118 MG cell line. Conversely, Ad5Luc1-CK1 gene delivery in U118 MG cells was about 100-fold higher than that of Ad5Luc1 while infection of the CAR-positive variant cell line yielded a comparable level of luciferase activity. Although the Ad5 fiber-knob competitively inhibited Ad5Luc1-mediated gene transfer in U118-hCAR-tailless (over 85% at 10 mg/ml), it had no Novel expanded tropism for cancer gene therapy MA Stoff-Khalili et al appreciable effect on Ad5/3Luc1, Ad5Luc1-CK1, and Ad5Luc1-CK2 transduction ( Figure 5 ). Thus, these data suggest that CAV1 knob-mediated gene delivery is CAR independent.
Ad3 receptor independence of CAV1 knob xenotype Ad
To further examine the distinct tropism of the CAV1 knob xenotype vector, interaction of the virus with the Ad3 receptor was indirectly studied with an Ad3 knobblocking experiment. In this case, the SKOV3.ip1 human ovarian cancer cell line was used because it abundantly expresses the Ad3 receptor. 29 Transgene expression mediated by Ad5/3Luc1 decreased with increasing concentrations of the Ad3 knob protein. In contrast, the purified Ad3 knob exhibited no influence on transduction with Ad5Luc1-CK1 ( Figure 6a ). Thus, these data show that Ad5Luc1-CK1 also displays an Ad3 receptorindependent tropism.
Enhanced gene transfer of Ad5Luc1-CK1 in cancer cell lines and primary ovarian cancer cells
Finally, we evaluated Ad5Luc1-CK1 transduction in a variety of cancer cells, which are known to be deficient in CAR. In all cases, the Ad5Luc1-CK1 vector achieved . This gene delivery level was also greatly improved relative to that of Ad5Luc1-CK2, further indicating the distinction between the tropism of the CAV-1 versus the CAV-2 knob. More importantly the excellent performance of Ad5Luc1-CK1 was also observed in primary ovarian cancer tissue samples, in which CAR levels are highly variable and often very low. 29 We utilized precision cut tissue slices of patient tumor samples, which represent a highly stringent ex vivo model system with three-dimensional characteristics for preclinical screening of adenoviral agents. Ad5Luc1-CK1 demonstrated increased gene transfer capability in ovarian cancer tissue slices (four patients) from 6.2-to 11.4-fold higher than Ad5Luc1 (Figure 6c) . Notably, the transduction capacity of Ad5Luc1-CK1 was superior overall compared to our Ad5/3Luc1 and Ad5Luc1-CK2, two chimeric vectors, which themselves have already shown remarkable infectivity enhancements in the same disease context previously. 14, 30 Of note, the Ad5Luc1-CK1 and Ad5Luc1-CK2-mediated gene transfer in fibroblasts and keratinocytes was poor.
Evaluation of Ad5Luc1-CK1 transduction in human liver tissue slices
To evaluate liver transduction of Ad5Luc1-CK1 in the most relevant context, the human liver, we infected precision-cut human liver tissue slices of three donors with Ad5Luc1 or Ad5Luc1-CK1. These precision-cut liver slices maintain the tissue architecture and contain the variety of cells normally found in liver. 31 As shown in Figure 7 the luciferase activity in human liver tissue slices infected with Ad5Luc1-CK1 was significantly less than luciferase activity in human liver tissue slices infected with Ad5Luc1 (Po0.01).
Discussion
For many target cancer cells it has been noted that low levels of the primary adenoviral receptor CAR may present a limiting factor that compromises the utility of Ad5 as a cancer gene therapy vector. To achieve the levels of efficiency required in the context of cancer gene therapy, it may be necessary to route conventional Ad via CAR-independent pathways. Therefore, achieving CARindependent and expanded tropism is one of the central tasks in Ad5 vector development for cancer gene therapy. To this end, we endeavored such vector design by genetic capsid engineering to replace the Ad5 fiber-knob with the corresponding structure from a nonhuman 'xenotype' Ad, CAV-1. Interest has recently extended to animal adenoviruses due to the desire to expand the choice of novel gene delivery vectors and thus provide more options for therapeutic strategies and design. In this regard, there are two canine isolates, serotypes 1 and 2, which may offer novel adenovirus infection pathways. 32 CAV-2 is one of the few non-human adenoviruses that have been investigated as a gene transfer vector for human applications. Particularly, a replicationdeficient CAV-2 vector has been constructed 14, 16, 33 and displayed a distinct tropism not exhibited by human 
Ad5
. 18 The tropism of CAV-2 fiber-knob has also been applied in the context of a chimeric Ad5 vector, which provided significant infectivity enhancement over an unmodified Ad5 virus.
14 CAV-1, however, has not been investigated for gene therapy purposes and represents a potential basis for achieving novel adenoviral tropism. In this regard, the data presented in this study represent the first attempt to explore the tropism of the CAV-1 knob.
The rationale of our study to generate a modified Ad5 vector containing the CAV-1 fiber-knob domain was established on the hypothesis that CAV-1 knob-mediated tropism is distinct from that of the CAV-2 knob. The reasons for this speculation include low DNA sequence homology 34, 35 and the reported differences in disease manifestations between CAV-1 and CAV-2. 19, 36, 37 In addition to structural, biophysical, and serological dissimilarities, the two viruses differ greatly in their biological properties. CAV-1 is known to cause allergic uveitis, called the 'blue eye syndrome' and rarely hepatitis, 32 whereas CAV-2 is known to preferentially infect the upper respiratory tract in young dogs, resulting in a mild disease called kennel cough. Neither the CAV-1 nor the CAV-2 receptor(s) have been rigorously identified. Indeed, our blocking experiments employing recombinant fiber-knob proteins revealed that the CAV-1 and CAV-2 fiber-knobs may share a common receptor as evidenced by the ability of the CAV-1 knob to inhibit Ad5Luc1-CK2 function. CAV-2 has been shown to bind directly to soluble recombinant human CAR and can utilize human or murine CAR for cell entry in vitro. 27 This finding, combined with our observation that both CAV-1 and CAV-2 knobs can competitively decrease Ad5-mediated gene transfer, suggest that this common receptor may likely be CAR.
Despite the result that both CAV-2 knob-mediated cell binding and gene delivery was competitively inhibited by the CAV-1 knob, the reverse phenomenon of CAV-2 knob blocking CAV-1 knob-mediated gene delivery could not be demonstrated. This observation may be due to a stronger interaction of the CAV-1 knob to the common receptor relative to the CAV-2 knob. However, the data may also be interpreted to support the idea that the CAV-1 knob may possess the ability to bind to a second receptor that is distinct from CAR. Interestingly, the implication that CAV-2 binds to a second receptor has been previously proposed based on gene delivery results both in the context of a CAV-2 vector 27 as well as an Ad5 chimeric vector.
14 If both CAV-1 and CAV-2 knobs have the ability to interact with secondary receptors in addition to CAR, then the secondary receptors for these two knobs may in fact be distinct based on our competitive inhibition results. Certainly, further studies would have to be conducted to validate these hypotheses. In addition, the interplay between these chimeric vectors and other confirmed and putative adenovirus receptors, such as integrins and heparin sulfate, should also be investigated.
Our major goal was to evaluate whether the CAV-1 'xeno-knob' paradigm would mediate expanded CARindependent tropism in CAR-negative target cancer cells. 
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Even though our data show that the CAV-1 knob may interact with CAR, we were able to achieve enhanced gene transfer with Ad5Luc1-CK1 in a CAR-independent manner. Interestingly, with respect to the CAV-2 knob, this same phenomenon was also observed.
14 Previous studies have utilized other chimeric strategies to attain infectivity enhancement, including the use of the Ad3 knob in the context of an Ad5 vector. The Ad3 receptor appears to be expressed at higher levels than CAR on ovarian cancer cells, therefore allowing 5/3 serotype chimeras to achieve greatly improved gene delivery. 30 Our data revealed the inability of the Ad3 fiber-knob protein to block Ad5luc-CK1 gene transfer, suggesting that this CAV-1 knob chimera, in addition to being CAR independent and distinct from the CAV-2 chimera, does not enter cells via the Ad3 receptor, putatively identified to be CD80, CD86 38 and CD46. 39 Variable expression of CAR has been documented in many cancer types, such as glioma, melanoma, breast cancer, prostate cancer, and rhabdomyosarcoma. 12, 13, 40, 41 It is known that for entry, viruses often exploit cellular receptors important in conserved pathways. Interestingly, previous studies suggest that CAR may act as a tumor suppressor, which could be linked to its frequent downregulation seen in highly tumorigenic cells. 4 Overcoming this deficiency, both Ad5Luc1-CK1 and Ad5-Luc1-CK2 14 show the ability to bind to and transduce CAR-deficient human glioma cells. Importantly, the transduction by Ad5Luc1-CK1 was augmented by 100-fold versus Ad5Luc1 and 75-fold versus Ad5Luc1-CK2 in glioma cells and superior to Ad5Luc1 and Ad5Luc1-CK2 in human ovarian cancer, osteosarcoma, and rhabdomyosarcoma cell lines. The significant difference of transduction in the various cancer cell lines between Ad5Luc1-CK1 and Ad5Luc1-CK2 also strongly supports our finding that the CAV-1 knob has a distinct tropism from the CAV-2 knob.
Both Ad5/3Luc1 29, 30 and Ad5Luc1-CK2 14 (Ad3 receptor independent) have been reported to exhibit increased infectivity enhancement in ovarian cancer cell lines and primary ovarian cancer cells. 29, 30 We endeavored to compare the infectivity enhancement of our seemingly CAR, Ad3 receptor, and CAV2 receptor-independent novel chimeric vector with Ad5/3Luc1 and Ad5Luc1-CK2 in ovarian cancer targets. There is mounting evidence that primary ovarian cancer express highly variable and often low amounts of CAR. 42 Thus, for preclinical evaluation of therapeutic agents, it is crucial to analyze cancer cell substrates that most closely and stringently resemble the patient setting. Gene transfer experiments were performed using primary ovarian 43 In primary ovarian cancer tissue slices, the infectivity enhancement by Ad5Luc1-CK1 was greater than that of Ad5/3Luc1 and Ad5Luc1-CK2. Of note, the gene transfer by Ad5Luc1-CK2 versus Ad5Luc1 was only moderate in the primary ovarian cancer tissue slices, further supporting the distinction between the CAV-1 and CAV-2 knobs. The levels of transduction we were able to achieve with Ad5Luc1-CK1 in the primary ovarian cancer samples are one of the highest we have observed in our experience with genetically modified adenoviruses.
Finally, we wished to evaluate the hepatotropism of Ad5Luc1-CK1, since CAV-1 has been reported to rarely cause hepatitis in dogs. 32 Importantly, our data showed that liver transduction of Ad5Luc1-CK1 was significantly lower compared to Ad5Luc1.
Herein, we have constructed a novel Ad5 chimeric xenotype CAV-1 knob vector, which exhibited expanded tropism and displayed superior transduction efficiency in a panel of cancer cells. Importantly, primary tumor tissue slices were also more efficiently transduced with this CAV-1 knob chimeric vector compared to other vectors. The enhanced infectivity appears to be both CAR and Ad3 receptor independent and was also distinct from the transduction pathway of the CAV-2 knob. These results highlight the potential of applying the CAV-1 xeno knob for effective adenovirus cancer gene therapy.
Materials and methods

Cell culture
Human embryonic kidney 293 cells, human embryonic rhabdomyosarcoma RD cells, CAR-negative human glioma U118 MG cells, human osteosarcoma MG63 cells, human ovarian cancer OV3 cells, human lung adenocarcinoma A549 cells, prostate cancer PC-3 cells, breast cancer MB-435 cells, Chinese hamster ovary (CHO) and teratocarcinoma PA-1 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human ovarian adenocarcinoma cell lines, Hey and SKOV3.ip1, were kind gifts from Drs Judy Wolf and Janet Price (M.D. Anderson Cancer Center, Houston, TX, USA), and Dr Timothy J Eberlein (Harvard Medical School, Boston, MA, USA), respectively. Primary fibroblasts and primary keratinocytes were obtained from Dr NS Banerjee, Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birnigham, AL, USA). All cells were maintained according to the suppliers' protocols. U118MG-hCAR-tailless cells, which express a truncated form of human CAR (comprising the extracellular domain, transmembrane, and the first two aa from the cytoplasmic domain) have been described previously. 28 These cells were propagated in a 50:50 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium (DMEM/F-12) supplemented with 10% (v/v) fetal calf serum (FCS, Gibco-BRL, Grand Island, NY, USA), L-glutamine 2 mM, penicillin (100 U/ml), and streptomycin (100 mg/ml). Stably transfected U118MG-hCAR-tailless cells were maintained in 400 mg/ml G418. Media and supplements were purchased from Mediatech (Herndon, VA, USA).
Human primary ovarian cancer tissue samples
Approval was obtained from the Institutional Review Board prior to initiation of studies on human tissues. Human ovarian primary tumors were obtained from epithelial ovarian carcinoma patients who have undergone debulking as primary therapy and have not had prior chemotherapy (Department of Surgery, University of Alabama at Birmingham (UAB)). Omental samples with extensive tumor infiltration were used to obtain samples since these specimens were the most easily obtained and had large tumor volumes from which adequate slices could be acquired (Krumdieck Tissue Slicer). Time from harvest to slicing was kept to a minimum (o2 h).
Human primary liver tissue samples
Human liver samples were obtained (Department of Surgery, UAB) from six seronegative donor livers that were to be transplanted into waiting recipients. Approval was obtained from the Institutional Review Board prior to initiation of studies on human tissue. All liver samples were flushed with University of Wisconsin (UW) solution (ViaSpan, Barr Laboratories, Inc. Pomona, NY, USA) prior to harvesting and kept on ice in UW solution until slicing. Time from harvest to slicing was kept at an absolute minimum (o2 h).
Krumdieck tissue slicer
The Krumdieck tissue slicing system (Alabama Research & Development 44 ) was used in accordance with the manufacturer's instructions and previously published techniques. 45 A coring device was used to create an 8 mm diameter core of ovarian cancer samples and human liver samples. This material was then placed in the slicer filled with ice-cold culture medium. Slice thickness was set at 250 mm using a tissue slice thickness gauge, and slices were cut using the reciprocating blade at 30 revolutions per minute (r.p.m.). Afterwards, the slices were stored in ice-cold culture media prior to culturing. The tissue slices were placed in six-well plates (one slice/well) containing 2 ml of complete media (RPMI with 1% antibiotics, 1% L-glutamine, and 10% FCS for ovarian cancer tissue slices and William's medium E with 1% antibiotics, 1% L-glutamine, and 10% FBS for liver tissue slices). The plates were then incubated at 371C/5% CO 2 in a humified environment under normal oxygen concentrations for 2 h. A plate rocker set at 60 r.p.m. was used to agitate the slices and to ensure adequate oxygenation and viability. 45, 46 Flow cytometry virus-binding assay Cells grown in T75 flasks were dislodged with EDTA (0.5 mmol) and resuspended in phosphate buffer solution (PBS) containing 1% bovine serum albumin (BSA). The cells (5 Â 10 5 cells/ml) were incubated with 100 viral particles of the respective vector, or buffer alone, for 1 h at 41C in 250 ml of PBS-BSA. After three washes with 4 ml of cold PBS-BSA, the cells were incubated with a 1:500 dilution of polyclonal rabbit anti-Ad5 hexon antiserum (Cocalico Biologicals, Reamstown, PA, USA) at 41C in 250 ml of PBS-BSA. The cells were washed again three times in 4 ml of cold PBS-BSA and incubated with 250 ml of a 1:150 dilution of FITC-labeled goat anti-rabbit IgG secondary antibody (Jackson Immunoresearch Labs, West Grove, PA, USA) for 1 h in PBS-BSA at 41C. The cells were analyzed at the UAB FACS Core Facility using a FACScan flow cytometer (Beckton Dickenson, San Jose, CA, USA).
For the recombinant knob competitive inhibition binding assay, A549 cells (5 Â 10 5 cells/ml in 100 ml) were incubated with 100 ml PBS-BSA alone or buffer containing 50 mg/ml recombinant fiber-knob at 41C for 30 min prior to addition of the viruses, and then antibody staining was performed as described above. To determine the percent blocking of virus binding by the addition of recombinant fiber-knob, histograms representing the staining intensity of cells preincubated in the absence or presence of recombinant knob protein were analyzed. First, the number of cells in the histogram peak representing cells preincubated in the absence of recombinant knob protein was determined by gating the staining to include 99% of the events detected. Then, the percent change in staining intensity was determined by subtracting the number of gated cells in the histogram peak representing cells blocked in virus binding by preincubated in the presence of recombinant knob protein.
Plasmid construction
The CAV-1 fiber-knob (537 bp) domain was amplified from viral DNA isolated from wild-type CAV-1 virus, a kind present from MD Morrison. 32 The following primers were applied: (forward) 5 0 -TATGGACTGGAC CTGATCCAAACGTT-3 0 and (reverse) 5 0 -TTTATCATTG ATTTTCCCCCACATAGGTGAAGG-3' (the stop codon TGA and the poly-adenylation signal TAAA are underlined). The plasmid pSHAFT is a cloning vector, which contains the Ad5 fiber gene with the knob region deleted and replaced by a small linker containing SmaI and EcoICRI restriction sites. 11 The plasmid was linearized by the enzymes SmaI and EcoICRI digestion giving two blunt ends. After gel purification, the PCR product containing the CAV-1 knob was ligated into the linearized pSHAFT resulting in pSHAFT-CK1. This plasmid contains the chimeric fiber gene encoding the complete Ad5 fiber shaft with the CAV-1 knob domain followed by a stop codon and polyadenylation sequence at the 3 0 end. The chimeric fiber gene in pSHAFT was digested with NcoI and MunI to liberate a 0.75 kb DNA fragment containing the carboxy terminus of the shaft and the CAV-1 knob domain and then ligated into the NcoI-MunI-digested shuttle vector PNEB.PK3. 6 11 resulting in pNEB.PK.3.6-CK1.
Generation of recombinant adenovirus
Recombinant adenovirus genomes containing the chimeric CAV-1 fiber-knob gene were generated by homologous recombination in BJ5183 Escherichia coli with Swallinearized rescue plasmid PVK700 and the fiber containing PacI-KpnI-fragment of pNEB.PK.3.6-CK1. PVK700 was derived from pTG3602, 47 but contains an almost compete deletion of the fiber gene and a firefly luciferase reporter gene driven by the cytomegalovirus (CMV) immediate early promoter in place of the E1 region. Genomic clones were subjected to sequencing and PCR analysis prior to transfection into 293 cells. Ad5Luc1 is a replication-defective E1-deleted unmodified control Ad5 vector containing a firefly luciferase reporter gene also driven by the CMV promoter.
11 Ad5Luc1-CK2, previously named as Ad5Luc1-CK, 14 is a replicationdefective E1-deleted Ad5-based vector containing the CAV-2 knob domain in a chimeric Ad5 fiber molecule. All vectors were propagated in 293 cells and purified by double cesium chloride (CsCl) ultracentrifugation and dialyzed against phoshate-buffered saline with Mg 2+ , Ca 2+ , and 10% glycerol. Final virus aliquots were analyzed for viral particle (vp) titer (absorbance at 260 nm) using a conversion factor of 1 OD ¼ 10 12 vp/ml. All vectors used in this study are essentially isogenic except for the fiberknob modifications. Using a common vector structure would standardize all conditions including the reporter expression cassette while allowing analysis of gene transfer efficiency as a consequence of varying the knob.
PCR validation of viral genome
Viral DNA was extracted from 1 Â 10 8 vp of Ad5Luc1, Ad5Luc1-CK1, and wild-type CAV-1 32 (Blood Mini Kit, Qiagen) and used as templates for PCR checking. To detect the presence of the Ad5 and CAV-1 fiber-knob genes, each viral genome was amplified in a PCR reaction mixture (Qiagen) containing 50 nM of primer pairs for 30 cycles of denaturation (941C, 1 min), annealing (541C, 1 min), and extension (721C, 1 min). The sequences of the various fiber-knob primer sets are as follows: Ad5 (forward) 5 0 -AGTGCTCATCTTATTATA AGA-3 0 , Ad5 (reverse) 5 0 -CACCACCGCCCTATCCTG AT-3'; CAV-1 (forward) 5 0 -TATGGACTGGACCTGATC CAAACGTT-3 0 and (reverse) 5 0 -TTTATCATTGATTTTCC CCCACATAGGTGAAGG-3 0 . PCR products were detected by 1% agarose gel electrophoresis with ethidium bromide staining.
Recombinant fiber-knob proteins
The Ad3, Ad5, and CAV-2 recombinant fiber proteins were produced and purified as described previously.
11,14
The recombinant knob domain of CAV-1 contains an N-terminus 6-histidine tag and was constructed in the pQE-81L expression plasmid (Qiagen, Hilden, Germany). The CAV-1 fiber-knob domain was amplified by PCR using the following primers: (forward) 5 0 -CAAACACGG ATCCCCTCAAAACAAAA-3 0 and (reverse) 5 0 -TTTAT CATTGATTTTCCCCCACATAGGTGAAGG-3 0 . The forward primer contains a two-basepair mutation (bold) to create a 5 0 -end BamHI restriction site (underlined). The PCR product containing the canine 1 fiber-knob region was digested with BamHI, gel purified, and ligated into BamHI-SmaI-digested pQE-81L. The resulting plasmid pQE-81L-CAV-1 was analyzed by restriction analysis and sequenced. Expression plasmids were introduced into E. coli, and the 6-His-containing fiber-knob proteins from bacterial cultures were purified under native conditions in nickel-nitrilotriacetic acid (Ni-NTA) agarose columns (Qiagen). Concentrations of the final purified knob protein were determined by the Lowry method (Bio-Rad). The trimerization ability of the recombinant CAV-1 fiber-knob was confirmed by Western blot analysis of boiled and unboiled purified knob proteins using a mouse monoclonal Penta-His antibody (Qiagen) and a horseradish peroxidase-conjugated anti-mouse immunoglobulin antibody at a 1:3000 dilution (Dako Corporation, CA, USA), followed by incubation with 3-3 0 -diaminobenzene peroxidase substrate (DAB; Sigma Company, USA).
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Western blot analysis
Aliquots of the Ad vectors equal to 5 Â 10 9 viral particles were diluted into Laemmli buffer and incubated at room temperature or 951C for 5 min and loaded onto a 4-20% gradient SDS-polyacrylamide gel (Bio-Rad, Hercules, CA, USA). Following electrophoresis protein separation, the protein samples were electroblotted onto a PVDF membrane. The primary 4D2 monoclonal antibody (recognizing the Ad5 fiber tail domain) was diluted 1:3000 (Lab Vision, Freemont, CA, USA) and used to probe the protein blot. Immunoblots were developed by addition of a secondary horseradish peroxidaseconjugated anti-mouse immuno-globulin antibody at a 1:3000 dilution (Dako Corporation, Carpentaria, CA, USA), followed by incubation with 3-3 0 -diaminobenzene peroxidase substrate for colorimetric development (DAB; Sigma Company, St Louis, MO, USA).
Ad-mediated gene transfer experiments
To determine gene transfer efficiency, 2 Â 10 4 cells were seeded per well in a 24-well plate. The next day, the respective cells were infected for 1 h at 371C with each vector at 100 vp/cell in 500 ml of infection medium containing 2% FCS. Luciferase activities of cell lysates were measured 48 h later using the Promega luciferase assay system (Madison, WI, USA). Experiments were performed in triplicates or six replicates (where indicated). Error bars represent standard deviations from the mean. For the gene transfer assays involving blocking conditions, recombinant fiber proteins at 0.5 and/or 1, 5, and 10 mg/ml final concentrations were incubated with the cells at 371C in transduction media 30 min prior to the addition of the virus. Following infection for 1 h, the cells were washed with transduction media to remove unbound virus and the blocking agent. All cells were maintained at 371C in an atmosphere of 5% CO 2 . For gene transfer assays of patient tissue slices, all viral infections were performed with 500 vp/cell in 2% FCS complete culture media. 31 The cell number for the tissue slices was estimated at 1 Â 10 6 cells/slice based on an approximate 10 cell slice thickness (B250 mm) and 8 mm slice diameter. Infections were allowed to proceed for 24 h. The medium was removed and replaced with 10% FCS-complete culture medium. The infected ovarian cancer tissue slices and human liver tissue slices were placed in cell culture lysis buffer (Promega) and homogenized with an ultra sonicator (Fisher Scientific Model 100) at a setting of 15 W for 10 s. The homogenate was centrifuged to pellet the debris, and the luciferase activities were measured using the Promega luciferase assay system (Madison, WI, USA). Experiments were performed in triplicate. Error bars represent s.d. from the mean. Protein concentration of the tissue homogenates was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA) to allow normalization of the gene expression data relative to the number of cells.
Statistics
Data are presented as mean values7s.d. Statistical differences among groups were assessed with a twotailed Student's t-test. P(*)o0.05 was considered significant.
